Business Context and Reporting Period
This Form 10-Q covers Celsion Corporation for the quarterly period ended June 30, 2003. The company is a clinical-stage biotechnology firm focused on developing thermotherapy systems for cancer and Benign Prostatic Hyperplasia (BPH) treatment. As of the reporting date, the company had no product sales and was in the pivotal Phase II clinical testing stage for its new equipment. The filing notes that the company has incurred substantial operating losses since inception and expects these to continue until regulatory approvals are obtained and commercialization begins.
Key Financial Metrics
| Metric | Three Months Ended June 30, 2003 | Nine Months Ended June 30, 2003 | Balance Sheet (June 30, 2003) |
|---|---|---|---|
| Revenue | $0 | $0 | N/A |
| Net Loss | $(2,849,466) | $(9,571,304) | N/A |
| Net Loss Attributable to Common Stockholders | $(2,899,012) | $(9,726,716) | N/A |
| Loss Per Share (Basic) | $(0.03) | $(0.09) | N/A |
| Operating Expenses | $2,854,714 | $9,585,767 | N/A |
| Cash and Cash Equivalents | N/A | N/A | $5,500,510 |
| Working Capital | N/A | N/A | $5,448,959 |
| Accumulated Deficit | N/A | N/A | $(53,546,798) |
Liquidity and Debt: The company reported no long-term debt on the balance sheet. Current liabilities totaled $1,093,903. Cash flow from operations was negative, with net cash used in operating activities totaling $6,286,208 for the nine-month period. Financing activities provided $10,914,523 in net cash, primarily from stock issuances and warrant exercises.
Material Changes vs. Prior Period
- Operating Loss: The loss from operations increased by 8% ($220,698) for the three months ended June 30, 2003, compared to the prior year quarter. For the nine-month period, the loss increased by 19% ($1,529,102).
- Research and Development (R&D): R&D expenses rose 17% in the quarter and 47% in the nine-month period. The nine-month increase was largely driven by a $2.175 million payment to Duke University (satisfied via stock issuance) and increased stock-based compensation.
- General and Administrative (G&A): G&A expenses decreased 6% in the quarter and 18% in the nine-month period. The nine-month decrease was primarily due to the absence of non-recurring legal settlement costs and former executive retirement accruals that were present in the 2002 period.
- Cash Position: Cash balances increased significantly from $928,819 at September 30, 2002, to $5,500,510 at June 30, 2003, driven by equity financing.
Outlook, Risks, and Management Commentary
Outlook and Funding: Management expects to expend approximately $12.5 million for the full fiscal year 2003 on clinical testing and overhead. The company secured a strategic agreement with Boston Scientific Corporation in January 2003, which included an initial $5 million investment (repaying a prior note) and a commitment for an additional $10 million upon meeting milestones. Management believes current resources are sufficient to fund operations through the end of fiscal year 2003.
Risks and Contingencies:
- Capital Dependence: The company has no committed sources of financing beyond the Boston Scientific agreement and must raise additional capital to continue operations. Failure to secure funding could force delays in clinical trials or loss of license rights.
- Regulatory Approval: No product revenues are expected until the company receives necessary governmental approvals for its new thermotherapy equipment.
- Accumulated Deficit: The company has an accumulated deficit of over $53 million and expects operating losses to continue.
Unusual Items: The nine-month period in 2002 included significant one-time costs related to a legal settlement with Warren C. Stearns and retirement payments to a former CEO, which are not present in the 2003 period.
Investor Verification Checklist
- Cash Runway: Verify if the $5.5 million cash balance and the Boston Scientific agreement are sufficient to cover the projected $12.5 million fiscal year 2003 burn rate without further dilution.
- Clinical Trial Status: Confirm the current status and timeline of the pivotal Phase II clinical trials for the breast cancer and BPH treatment systems.
- Boston Scientific Milestones: Review the specific milestones required to trigger the additional $10 million investment from Boston Scientific.
- Stock-Based Compensation: Assess the impact of stock-based compensation on future cash burn, noting the significant non-cash expense recognized in the current period.
- Preferred Stock Obligations: Review the terms of the Series A and Series B Convertible Preferred Stock, including dividend requirements and conversion rates.